Intranasal administration of deferoxamine to iron overloaded patients.
We examined the effect of intranasal administration of deferoxamine on iron excretion in seven patients with iron overload secondary to chronic transfusion therapy. Deferoxamine was administered in doses of 0.75 to 3.0 gm given over 12 hours in a variety of dosing schedules. There was a probable, though not significant, dose response relationship between the amount of iron excreted and the dose administered. The amount of iron excreted was 10%-15% of that obtained using the same dosage of deferoxamine given by the subcutaneous route over the same time period. Hourly administration was more effective than less frequent administration. Addition of taurodeoxycholate to deferoxamine did not increase its absorption as measured by the levels of iron excretion. Side effects were few and consisted mainly of mild nasal irritation and a bad taste in the mouth. Nasal administration of deferoxamine may be a useful adjunct to iron chelation in patients receiving chronic transfusion therapy, particularly in those who are noncompliant with parenteral means of administration.
Gordon
G S
GS
Department of Medicine, University of Colorado Health Sciences Center, Denver.
Ambruso
D R
DR
Robinson
W A
WA
Githens
J H
JH
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005293:Ferritins / Q000097:blood; D006801:Humans; D007279:Injections, Subcutaneous; D007501:Iron / Q000506:poisoning* / Q000652:urine; D010349:Patient Compliance; D013657:Taurodeoxycholic Acid / Q000494:pharmacology
D013657:Taurodeoxycholic Acid; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine